Gender differences in pharmacokinetics of tacrolimus and their clinical significance in kidney transplant recipients

Gender Medicine

Volumn 8, Issue 1, 2011, Pages 23-31

  Velickovi Radovanovi, Radmila ^a,b,e   Mikov, Momir ^c   Paunovi, Goran ^b   Djordjevi, Vidojko ^a,b   Stojanovi, Mariola ^d   Cvetkovi, Tatjana ^a,b   Cati Djordjevi, Aleksandra ^a  

^a UNIVERSITY OF NI   (Serbia)

^b Clinical Centre Nis   (Serbia)

^c UNIVERSITY OF NOVI SAD   (Serbia)

^d Public Health Institute   (Serbia)

^e Faculty of Medicine   (Serbia)

Author keywords

gender differences; kidney transplantation; pharmacokinetics; tacrolimus

Indexed keywords

BASILIXIMAB; DILTIAZEM; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; TACROLIMUS;

ADULT; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXPOSURE; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AREA UNDER CURVE; DRUG MONITORING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SEX FACTORS; TACROLIMUS;

EID: 79954555328     PISSN: 15508579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genm.2011.01.003     Document Type: Article

References (38)

1. J.B. Schwartz The influence of sex on pharmacokinetics [published correction appears in Clin Pharmacokinet. 2004;43:732] Clin Pharmacokinet 42 2003 107
2. D.J. Greenblatt, and L.L. Moltke Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs J Clin Pharmacol 48 2008 1350 1355
3. R. Wolbold, K. Klein, and O. Burk Sex a major determinant of CYP3A4 expression in human liver Hepatology 38 2003 978 988 (Pubitemid 37221681)
4. Y.H. Chen, K.L. Yheng, and L.Z. Chen Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese kidney transplantation recipients Transplant Proc 37 2005 4246 4250 (Pubitemid 43016001)
5. Y. Dai, M.F. Hebert, and N. Isoherranen Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro Drug Metab Dispos 34 2006 836 847
6. S. Masuda, and K. Inui An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients Pharmacol Therapeut 112 2006 184 198 (Pubitemid 44301492)
7. D.R. Kuypers, K. Claes, and P. Evenepoel Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: A prospective study in one hundred de novo kidney transplant recipients Clin Pharmacokinet 43 2004 741 762 (Pubitemid 39159005)
8. G. Filler, R. Grygas, and I. Mai Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with kidney transplants Nephrol Dial Transp 12 1997 1668 1671 (Pubitemid 27346294)
9. G.D. Anderson Gender differences in pharmacological response Int Rev Neurobiol 83 2008 1 10
10. V. Haufroid, M. Mourad, and V. Van Kerckhove The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients Pharmacogenetics 16 2004 147 154 (Pubitemid 38373108)
11. E. Tanaka Gender-related differences in pharmacokinetics and their clinical significance J Clin Pharm Ther 24 1999 339 346 (Pubitemid 29520783)
12. I. Bartlomiejczyk, D. Zochowska, and J. Sanko-Resmer Therapeutic monitoring of tacrolimus concentrations in blood of renal and liver transplant recipients: comparison of microparticle enzyme immunoassay and enzyme multiplied immunoassay methods Transplant Proc 38 2006 94 96
13. S. Satoh, H. Kagaya, and M. Saitro Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients Br J Clin Pharmacol 66 2008 207 214
14. C. Aquilante, T. Langaee, and P. Anderson Multiple PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms Clinic Chimic Acta 372 2006 195 198 (Pubitemid 44286754)
15. D. Cattaneo, S. Baldelli, and N. Perico Pharmacogenetics of immunosuppressants: Progress, pitfalls and promises Am J Transplant 8 2008 1374 1383 (Pubitemid 351989490)
16. K. Iwasaki Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics Drug Metab Pharmacokinet 22 2007 328 335
17. N. Xin-Min, G. Rong, and Z. Hong-Shan Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients J Cent South Univ Technol 12 2005 310 313
18. V. Armstrong, and M. Oellerich New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine Clin Biochem 34 2001 9 16 (Pubitemid 32178500)
19. B. Kahan, P. Keown, G. Levy, and A. Johnston Therapeutic drug monitoring of immunosuppressant drugs in clinical practice Clin Ther 24 2002 330 350 (Pubitemid 34275858)
20. K. Hoshinaga, A. Aikawa, and M. Murai Regimen of tacrolimus-based immunosuppression with basiliximab, mycophenolate mofetil, and low-dose steroid reduces acute rejection in kidney transplants Transplant Proc 37 2005 1762 1763 (Pubitemid 40790822)
21. S. Lam, N. Partovi, L.S. Ting, and M.H. Ensom Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: Fact or fiction? Ann Pharmacother 42 2008 1037 1047
22. D. Anglicheau, C. Legendre, and E. Thervet Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: From retrospective analyses to prospective studies Transplant Proc 39 2007 2142 2144 (Pubitemid 47418130)
23. European Association of Urology (EAU) Online guidelines http://www.uroweb.org/professional-resources/guidelines/ Accessed July 2009
24. C. Le Guellec, M. Bchler, and B. Giraudeau Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy Eur J Clin Pharmacol 57 2002 805 811 (Pubitemid 34143339)
25. M. Antignac, B. Barrou, and R. Farinotti Population pharmacokinetics and bioavailability of tacrolimus in kidney transplantation patients Br J Clin Pharmacol 64 2007 750 757 (Pubitemid 350222052)
26. N.A. Undre Pharmacokinetic of tacrolimus-based combination therapies Nephrol Dial Transpl 18 Suppl 1 2003 12 15
27. R. Press, B. Ploeger, and J. Hartigh Explaining Variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients Ther Drug Monitoring 31 2009 187 197
28. P. Katsakiori, E. Papapetrou, and G. Sakellaropoulos Factors affecting the long-term response to tacrolimus in renal transplant patients: Pharmacokinetic and pharmacogenetic approach Int J Med Sci 7 2010 94 100
29. M.F. Paine, S.S. Ludington, and M.L. Chen Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos 33 2005 426 433 (Pubitemid 40279944)
30. J. Molpeceres, M. Chacn, and M. Guzmn Dependency of cyclosporine tissue distribution and metabolism on the age and gender of rats after a single intravenous dose Int J Pharm 197 2000 129 141 (Pubitemid 30125784)
31. K. Jørgensen, J.V. Povlsen, and S. Madsen C-2(2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients Nephrol Dial Transpl 17 2002 1487 1490
32. S. Chiaramonte, D. Dissegna, and C. Ronco Monitoring of immunosuppressive therapy in kidney transplanted patients C. Ronco, S. Chiaramonte, G. Remuzzi, Kidney Transplantation 2005 Karger Basel, Switzerland 73 86 (Pubitemid 43264975)
33. F.G. Balbontin, B. Kiberd, and J. Squires Tacrolimus monitoring by simplified sparse sampling under the concentration time curve Transplant Proc 35 2003 2445 2448 (Pubitemid 37378028)
34. K.M. Wong, C.C. Shek, K.F. Chan, and C.S. Li Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients Am J Kidney Dis 35 2000 660 666
35. K. Grego, M. Arnol, and A.F. Bren Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor kidney graft recipients Transplant Proc 39 2007 3093 3097 (Pubitemid 350251493)
36. A. Kandus, K. Grego, and M. Arnol Effective immunoprophylaxis with basiliximab plus triple therapy in renal transplantation: Five-year single-center experience Transplant Proc 38 2006 2853 2855 (Pubitemid 44737939)
37. B.M. Lee, C.K. Oh, and S.H. Jin Effect of basiliximab on renal allograft rejection within one year after transplantation Transplant Proc 38 2006 2025 2028 (Pubitemid 46068472)
38. P. Salis, C. Caccamo, and R. Verzaro The role of basiliximab in the evolving renal transplantation immunosuppression protocol Biologics 2 2008 175 188